Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.85 |
| ▸ | BRD2 | P25440 | 4/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | TSPO | P30536 | 1/20 | 0.65 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.65 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197604 | 0.94 | BRD4 (0.77) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL3211139 | 0.93 | BRD4 (0.75) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL3198871 | 0.93 | BRD4 (0.74) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL3198838 | 0.93 | BRD4 (0.83) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL3200319 | 0.92 | BRD4 (0.73) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL13028879 | 0.92 | BRD4 (1.00) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL3210275 | 0.92 | BRD4 (0.75) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL3189634 | 0.92 | BRD4 (0.73) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL3189663 | 0.92 | BRD4 (0.72) | BRD4BRD2ADORA3TSPODNER | |
| SCHEMBL25092048 | 0.92 | BRD4 (0.83) | BRD4BRD2ADORA3TSPODNER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | claimed |
| EP-2863923-B1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS FOR THE TREATMENT OF LYMPHOMAS | ONCOETHIX GMBH (CH) | 2019-05-08 | — | — | EP | claimed |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-08 | — | — | US | claimed |
| EP-3154549-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-3137086-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-03-08 | — | — | EP | claimed |
| US-20160375032-A1 | METHOD OF TREATING NON-SMALL-CELL LUNG CANCER USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2016-12-29 | — | — | US | claimed |
| US-20160158245-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2016-06-09 | — | — | US | claimed |
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | ONCOETHIX GMBH (CH) | 2016-06-09 | — | — | US | claimed |
| WO-2015189814-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2015-12-17 | — | — | WO | claimed |
| WO-2015168555-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-11-05 | — | — | WO | claimed |
| US-9125915-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-09-08 | — | — | US | claimed |
| WO-2015078931-A1 | METHOD OF TREATING NEUROBLASTOMAS USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-06-04 | — | — | WO | claimed |
| WO-2015018523-A1 | A NOVEL BET-BRD INHIBITOR FOR TREATMENT OF SOLID TUMORS | ONCOETHIX SA (CH) | 2015-02-12 | — | — | WO | claimed |
| US-20140107107-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2014-04-17 | — | — | US | claimed |
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | claimed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | claimed |
| EP-2239264-A1 | ANTITUMOR AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-10-13 | — | — | EP | claimed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | claimed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | claimed |
| WO-2022132049-A1 | TREATING CANCERS USING BET INHIBITORS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-06-23 | — | — | WO | disclosed |
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| EP-2863923-B1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS FOR THE TREATMENT OF LYMPHOMAS | ONCOETHIX GMBH (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-9968620-B2 | Methods of treating lymphoma using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9968619-B2 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9956228-B2 | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9901583-B2 | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-02-27 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9820992-B2 | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9795612-B2 | Pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3226898-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170273988-A1 | METHODS OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-09-28 | — | — | US | disclosed |
| US-9757385-B2 | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-08 | — | — | US | disclosed |
| US-20170151255-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-01 | — | — | US | disclosed |
| US-20170095484-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| EP-3139959-A1 | METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-03-15 | — | — | EP | disclosed |
| US-20170065607-A1 | METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-03-09 | — | — | US | disclosed |
| EP-3137085-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170049784-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-02-23 | — | — | US | disclosed |
| US-20160375032-A1 | METHOD OF TREATING NON-SMALL-CELL LUNG CANCER USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2016-12-29 | — | — | US | disclosed |
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | ONCOETHIX GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160158245-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2016-06-09 | — | — | US | disclosed |
| WO-2016090219-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20150335656-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-11-26 | — | — | US | disclosed |
| WO-2015169951-A1 | METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015168621-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-11-05 | — | — | WO | disclosed |
| US-9125915-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2900221-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix SA (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2863923-A1 | METHOD OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix SA (CH) | 2015-04-29 | — | — | EP | disclosed |
| WO-2014068402-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2014-05-08 | — | — | WO | disclosed |
| US-20140107107-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2014-04-17 | — | — | US | disclosed |
| WO-2014001356-A1 | METHOD OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20130261109-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-03 | — | — | US | disclosed |
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2239264-A1 | ANTITUMOR AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | BRD4, BRD7, BCL6 | BRD4 1/4885BRD2 10/4885ADORA3 2844/4885 |
| US-20130261109-A1 | ANTITUMOR AGENT | BRPF3, BRDT, BRD4 | BRD4 3/4885BRD2 5/4885ADORA3 3430/4885 |
| US-20170049784-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | MCL1, FLT3, HCLS1 | BRD4 137/4885BRD2 206/4885ADORA3 343/4885 |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | CCR10, HRH4, H1-10 | BRD4 22/4885BRD2 128/4885ADORA3 218/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | BRD4 2/4885BRD2 4/4885ADORA3 3692/4885 |
| US-20140107107-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | BRD4 97/4885BRD2 121/4885ADORA3 126/4885 |
| US-20170151255-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC19A2, TBXA2R | BRD4 15/4885BRD2 53/4885ADORA3 746/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | BRD4 2/4885BRD2 4/4885ADORA3 3692/4885 |
| US-20100286127-A1 | ANTITUMOR AGENT | BRDT, HDAC1, BRPF3 | BRD4 4/4885BRD2 8/4885ADORA3 3996/4885 |
| US-20160375032-A1 | METHOD OF TREATING NON-SMALL-CELL LUNG CANCER USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CCR10 | BRD4 20/4885BRD2 137/4885ADORA3 468/4885 |
| US-20170095484-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ALK, MALT1, BCL6 | BRD4 356/4885BRD2 441/4885ADORA3 644/4885 |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | BRD4 265/4885BRD2 318/4885ADORA3 76/4885 |
| US-20170273988-A1 | METHODS OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | BCL6, BCL6B, BCL9 | BRD4 10/4885BRD2 45/4885ADORA3 1911/4885 |
| US-20160158245-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ABL1, BCR, FLT3 | BRD4 16/4885BRD2 62/4885ADORA3 434/4885 |
| US-20150335656-A1 | ANTITUMOR AGENT | BRPF3, BRDT, BRD4 | BRD4 3/4885BRD2 5/4885ADORA3 3430/4885 |
| US-20170065607-A1 | METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | CDK10, HRH4, H1-10 | BRD4 15/4885BRD2 221/4885ADORA3 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.